 Connection
Wells Messersmith to Immunoglobulin G
This is a "connection" page, showing publications Wells Messersmith has written about Immunoglobulin G.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.114 |
|
|
|
-
Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Boh?rquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2462-70.
Score: 0.089
-
Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. 2017 Oct 01; 123(19):3843-3854.
Score: 0.025
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|